Biogen announces retirement of directors Nancy Leaming and Brian Posner effective at 2022 annual meeting

BIOGEN INC.

Nancy Leaming and Brian Posner will retire from Biogen Board effective at the 2022 annual meeting of stockholders.
Both directors have served since 2008; Leaming on Audit Committee, Posner as Chair of Compensation Management and Development Committee.
Retirements are not related to any disagreement with the Board or the Company.
No replacements have been announced yet.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nancy L. Leaming

Director

BIIB · BIOGEN INC.

Filed: January 31, 2022, 6:59 PM ET

Pursuant to the retirement provisions set forth in the Company’s Corporate Governance Principles, Nancy L. Leaming will also retire from the Board effective as of the Company’s 2022 annual meeting of stockholders.

Departed

Brian S. Posner

Director

BIIB · BIOGEN INC.

Filed: January 31, 2022, 6:59 PM ET

On January 25, 2022, Brian S. Posner notified Biogen Inc. (the “Company” or “Biogen”) that he will retire from the Biogen Board of Directors (the “Board”) effective as of the Company’s 2022 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy L. Leaming departed as Director at BIOGEN INC..

Action: retire
Role: Director

Exact text from the filing

Pursuant to the retirement provisions set forth in the Company’s Corporate Governance Principles, Nancy L. Leaming will also retire from the Board effective as of the Company’s 2022 annual meeting of stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian S. Posner departed as Director at BIOGEN INC..

Action: retire
Role: Director

Exact text from the filing

On January 25, 2022, Brian S. Posner notified Biogen Inc. (the “Company” or “Biogen”) that he will retire from the Biogen Board of Directors (the “Board”) effective as of the Company’s 2022 annual meeting of stockholders.

View on SEC.gov

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-022381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.